Alpha 2.0
Login Register
» Articles » PMID: 23965900

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2013 Aug 23
PMID 23965900
Citations 33
Authors
Aurelien Marabelle
Holbrook Kohrt
Ronald Levy
Affiliations
Soon will be listed here.
Abstract

Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

Citing Articles

Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.

Duerinck J, Lescrauwaet L, Dirven I, Delhaye J, Stevens L, Geeraerts X Neuro Oncol. 2024; 26(12):2208-2221.

PMID: 39406392 PMC: 11630548. DOI: 10.1093/neuonc/noae177.

Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.

Pitiot A, Heuze-Vourch N, Secher T Antibodies (Basel). 2022; 11(3).

PMID: 36134952 PMC: 9495858. DOI: 10.3390/antib11030056.

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8 T lymphocyte/Treg cell balance.

Carmenate T, Montalvo G, Lozada S, Rodriguez Y, Ortiz Y, Diaz C Front Immunol. 2022; 13:974188.

PMID: 36059465 PMC: 9428827. DOI: 10.3389/fimmu.2022.974188.

Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors.

Cuburu N, Bialkowski L, Pontejo S, Sethi S, Bell A, Kim R Proc Natl Acad Sci U S A. 2022; 119(26):e2116738119.

PMID: 35749366 PMC: 9245622. DOI: 10.1073/pnas.2116738119.

Intratumoral immunotherapy relies on B and T cell collaboration.

Sagiv-Barfi I, Czerwinski D, Shree T, Lohmeyer J, Levy R Sci Immunol. 2022; 7(71):eabn5859.

PMID: 35622903 PMC: 9254330. DOI: 10.1126/sciimmunol.abn5859.

References
1.
Quezada S, Peggs K, Simpson T, Allison J . Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011; 241(1):104-18. PMC: 3727276. DOI: 10.1111/j.1600-065X.2011.01007.x. View
2.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View
3.
Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell R, Zhou G . Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013; 123(6):2447-63. PMC: 3668834. DOI: 10.1172/JCI64859. View
4.
Fransen M, van der Sluis T, Ossendorp F, Arens R, Melief C . Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013; 19(19):5381-9. DOI: 10.1158/1078-0432.CCR-12-0781. View
5.
Simmons A, Moskalenko M, Creson J, Fang J, Yi S, VanRoey M . Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 2008; 57(8):1263-70. PMC: 11031020. DOI: 10.1007/s00262-008-0451-3. View